Clinical Trials
96 trialsBOSS
AstraZeneca
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
Dana-Farber Cancer Institute
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Memorial Sloan Kettering Cancer Center
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
M.D. Anderson Cancer Center
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Cardiotoxicities in Patients Receiving BTKi
Dana-Farber Cancer Institute
HMvax-Regist
Wake Forest University Health Sciences
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
City of Hope Medical Center
PACE-CLL
Sunnybrook Health Sciences Centre
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL
Shanghai Ming Ju Biotechnology Co., Ltd.
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
M.D. Anderson Cancer Center
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
University of Pennsylvania
BRIO
SecuraBio
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Hutchmed
2019-KOE-001
Baptist Health South Florida
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Academic and Community Cancer Research United
Early Intervention With Acalabrutinib in Patients With High Risk CLL
Weill Medical College of Cornell University
RIVe-CLL/SLL
Virginia Commonwealth University
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
Ohio State University Comprehensive Cancer Center
Collecting and Storing Blood Samples From Patients With Cancer
Rutgers, The State University of New Jersey
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
SecuraBio
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
CTI BioPharma
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Fred Hutchinson Cancer Center
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
Dana-Farber Cancer Institute
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alliance for Clinical Trials in Oncology
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
University of Wisconsin, Madison
Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab
Abramson Cancer Center at Penn Medicine
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
Scripps Health
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
University of California, San Diego
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Nordic Nanovector
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
University of Texas Southwestern Medical Center
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
Esanex Inc.
Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia
Maastricht Radiation Oncology
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia
Dartmouth-Hitchcock Medical Center
Lenalidomide and Obinutuzumab for Previously Untreated CLL
University of California, San Diego
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
Boehringer Ingelheim
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Masonic Cancer Center, University of Minnesota
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Masonic Cancer Center, University of Minnesota
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
COMBOSTAT
The Methodist Hospital Research Institute
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
University of Michigan Rogel Cancer Center
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
S-BR
University of Arizona